A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

Key Inclusion Criteria (for Part 3): * A histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma which is metastatic (measurable disease). * Documented KRAS- or BRAF- tumor mutation. * Previously treated with or unsuitable for treatment with 5-Fluorouracil (5-FU), oxaliplatin, irinotecan and, if available, bevacizumab. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. * Additional criteria exist. Key Exclusion Criteria (for Part 3): * Uncontrolled or symptomatic brain metastases (if the patient has brain metastases and is on steroids, the steroid dose must have been stable for at least 30 days). * History of central serous retinopathy, retinopathy visible at baseline that would be considered a risk factor for central serous retinopathy or retinal vein occlusion. * Concomitant malignancies or previous malignancies with less than a 2-year disease free interval at the time of enrollment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stage A low grade prostate cancer may enroll irrespective of the time of diagnosis. * Prior treatment with a MEK inhibitor. * Treatment with prior chemotherapy, anticancer immunotherapy, monoclonal antibodies or other protein or peptide therapeutics within 21 days of the first dose of study drug. * Treatment with a small molecule targeted agent or anticancer hormonal therapy within 14 days of the first dose of study drug. * Treatment with prior radiotherapy within 28 days of initiating study drug (if the radiation portal covered ≤ 10% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy). * Major surgery within 4 weeks or minor surgery within 7 days prior to the first dose of study drug. * Known positive serology for the human immunodeficiency virus (HIV), hepatitis C, and/or active hepatitis B. * Additional criteria exist.